Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Forty patients with severe bone disease and chronic renal failure were treated with 1 alpha-hydroxycholecalciferol (1 alpha-OHD3) or 1,25-dihydroxycholecalciferol (1,25(OH)2D3) for 7--49 months (total = 738 patient months). There were symptomatic, biochemical and radiographic improvements in the majority of patients (greater than 70 per cent). Paired bone biopsies, taken before and during treatment in 26 patients, showed no change in bone matrix area, whereas matrix area decreased in a control group of 26 patients over the same period. There were small but consistent decreases in bone marrow fibrosis and in bone cell (osteoblast and osteoclast) counts in treated patients but not in controls. However, the proportion of patients who showed histological 'cure', in the sense of complete reversal of marrow fibrosis or excess osteoid was no greater in the treated than in the control group...

Type

Journal article

Journal

The Quarterly journal of medicine

Publication Date

04/1979

Volume

48

Pages

289 - 322

Keywords

Bone and Bones, Humans, Bone Diseases, Metabolic, Kidney Failure, Chronic, Phosphates, Calcium, Hydroxycholecalciferols, Dihydroxycholecalciferols, Parathyroid Hormone, Alkaline Phosphatase, Hydroxyproline, Adolescent, Adult, Middle Aged, Child, Child, Preschool, Female, Male